Home » Newsletters » BioWorld Science

BioWorld Science

May 19, 2000

View Archived Issues

Zambon and Sheffield file for MSI-Albuterol approval via European centralized procedure

Novel therapeutic approaches for diabetic nephropathy explored

Incara advances research programs during first four months of the year

RxKinetix and Elan form joint venture for oral mucositis drug development

Interneuron highlights Q2 developments

Ciblex's CBX-10913 blocks inflammation in mice

Exelon gains Canadian approval as new treatment for Alzheimer's disease

Yale receives NIDA grant to advance Cantab's anticocaine vaccine

CV Therapeutics moves CVT-510 to phase III

EntreMed responds to premature disclosure of trial data

New inhibitor of ICAM-1/LFA-1-mediated cell adhesion produced by Streptomyces

Squalamine demonstrates preclinical activity in retinopathy

SuperGen anticancer compound subject of new CRADA

Pantoprazole now available for more uses

Lilly's Evista receives additional approval in E.U. for the treatment of osteoporosis

Pierre Fabre becomes Recordati's partner for lercanidipine in France

New treatment option for patients with atrial fibrillation/atrial flutter introduced in U.S.

First market launch for novel antiepileptic drug Keppra

Leflunomide analogue protects against renal allograft rejection in combination with ciclosporin

Cognetix and collaborators discover novel conopeptides interacting with voltage-gated K+ channels

Selective RXR agonists designed at Allergan particularly useful for skin-related diseases

Two new series of PDE5 inhibitors claimed by Pfizer

Imidazolones targeting Y5 receptors described by BMS as anorectic agents

Antisense oligonucleotides for modifying bcl-x expression in the Isis pipeline

Abbott continues to search for new ketolide antibacterial agents

FDA denies approval for Refludan in acute coronary syndrome

Major approval obtained for Mylotarg, the first antibody-targeted chemotherapy product

Clinical data support equivalence of Gengraf and Neoral; Gengraf approved by FDA

Transplant 2000 news: novel strategy for preventing chronic rejection in renal allograft recipients

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...